Combination therapy in rheumatoid arthritis: metaanalysis

Area of Science:

• Rheumatology
• Biostatistics
• Evidence-based medicine

Background:

• Meta-analysis synthesizes research findings using rigorous methods to minimize bias.
• Assessing combination therapy in rheumatoid arthritis (RA) presents unique methodological challenges.
• Currently, limited meta-analyses exist for RA combination therapy, with one combining diverse treatment agents.

Purpose of the Study:

• To review critical methodological issues in the meta-analysis of combination therapy for rheumatoid arthritis.
• To provide recommendations for future meta-analyses in this field.

Main Methods:

• Literature review focusing on meta-analysis methodologies.
• Critical appraisal of existing meta-analyses concerning rheumatoid arthritis combination therapy.
• Examination of standardization and endpoint selection in clinical trials.

Main Results:

• Only one published meta-analysis on RA combination therapy exists, which aggregated trials with different agents.
• Significant methodological variations exist across existing RA combination therapy trials.
• Lack of standardized study designs and agreed-upon endpoints hinders robust meta-analysis.

Conclusions:

• Future meta-analyses of RA combination therapy require standardized study designs and the inclusion of universally accepted endpoints (e.g., WHO/ILAR/ACR).
• Adherence to established meta-analysis guidelines, such as those from the Cochrane Collaboration, is crucial.
• Standardization will enhance the reliability and validity of synthesized evidence for RA combination therapy.